Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, as long as it stays under $4 - it's not certain the public offering will even be completed
I'm a little worried, but the reward of selling out of shares early is equally as tempting
I'm holding long, probably won't add any more in the next few days tho
As long as the price stays under $4 , I'm not sure any new shares are being issued.
I'm long
EKSO AND TOYOTA:
Just purchased 676 shares EKSO
1776 total shares, 5.39 cost Basis
perhaps better than my brokerage - who showed me monday's closing price all day long (I had to look to the website for a delayed quote), and could not purchase.
I had been using optionshouse, but I'm thinking I'll switch.
As to KPISME
Meh, we will see. Rapid swings can happen just as fast in either direction. I hope you can get a position in time if/when they happen.
Industrial contracts are around the corner IMO
Back up we go? After Hours: $ 4.24
http://ir.stockpr.com/eksobionics/quote
I'm long EKSO
I also wonder what Keith says. But look at volume.
1.59m volume as of right now
That seems huge to me. If shares the offering complete early, we could see huge gains.
I'm long EKSO
Well, as long as the company doesn't go under before TALOS is released -
I'm pretty happy with any direction it heads meanwhile.
You might say I know how to trim my sails.
Regarding TALOS' success: The alternative option is that DARPA, with some of the smartest people in the world, will have spent millions of dollars and years of work with nothing to show for it. I'm pretty sure this won't happen - at least not to exoskeletons. The capabilities are too real, and autonomous robots are too far off.
I'm long
It's called LONG for a reason, 1 day swings - even dramatic ones, will pail in comparison to broader realities.
It's restricted, and for good reason. I suggest following exec moves
"Each of our directors and executive officers have agreed that for a period of 90 days from the effective date of this offering, they will be subject to a lockup prohibiting certain sales, transfers or hedging transactions in our securities held by them. See “Underwriting - No Sales of Similar Securities.”
from: http://ir.eksobionics.com/all-sec-filings#document-11517-0001144204-16-117206
The shares previously issued that were convertible at a higher price are being converted with anti-dilution provisions.
Essentially, I view this as EKSO's way to be FAITHFUL TO OLD INVESTORS.
A key point, when you consider their actions.
I'm long EKSO
It's called LONG for a reason, 1 day movements don't concern me
It's restricted, and for good reason. I suggest following exec moves
"Each of our directors and executive officers have agreed that for a period of 90 days from the effective date of this offering, they will be subject to a lockup prohibiting certain sales, transfers or hedging transactions in our securities held by them. See “Underwriting - No Sales of Similar Securities.”
The shares previously issued that were convertible at a higher price are being converted with anti-dilution provisions.
Essentially, I view this as EKSO's way to be FAITHFUL TO OLD INVESTORS.
A key point, when you consider their actions.
I'm long EKSO
It was $ 4.50 premarket when I looked
http://ir.stockpr.com/eksobionics/quote
Definitely a gouge, but stock's aren't for the weak stomached.
I'm long
Issued at $4.00 per share = dilutoin; but I'm going to buy.
I think the trajectory is good, despite a little dilution.
RICHMOND, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (EKSO), a robotic exoskeleton company, today announced approval to list its common stock on the Nasdaq Capital Market. The Company’s common stock will begin trading under the symbol “EKSO” at the opening of trading on August 9, 2016.
The Company also announced today the pricing of the previously announced underwritten public offering of 3,750,000 shares of its common stock to new and existing investors at a price to the public of $4.00 per share. The offering is expected to close on or about August 12, 2016, subject to customary closing conditions. The Company expects to receive net proceeds of approximately $13.7 million from the sale of common stock in the offering, after deducting the underwriting discounts and estimated offering expenses payable by it. The Company intends to use the net proceeds from this offering for its operations, including, but not limited to, increasing its investments (i) in its clinical, sales and marketing initiatives to accelerate adoption of the Ekso robotic exoskeleton in the rehabilitation market; (ii) in its research, development and commercialization activities with respect to an Ekso robotic exoskeleton for home use and/or (iii) in the development and commercialization of able-bodied exoskeletons for industrial use, as well as for working capital and other general corporate purposes.
Cowen and Company is acting as the sole book-running manager for the offering, SunTrust Robinson Humphrey is acting as lead manager in the offering and B. Riley & Co. is acting as co-manager in the offering. The Company has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of common stock to cover overallotments, if any.
I'm long EKSO
CERTNAS form: "Certification by the NASDAQ Stock Exchange approving securities for listing"
A document FILED with the SEC - although it's a placeholder
http://ir.eksobionics.com/all-sec-filings#document-11520-9999999997-16-024912
SEC FILING, REGARDING NASDAQ APPROVAL:
"Our common stock is currently quoted on the OTC Markets under the symbol “EKSO.” The last reported sale price of our common stock on the OTC Markets (OTCQB) on August 5, 2016 was $6.24 per share. We have applied for listing of our common stock on The NASDAQ Capital Market under the symbol “EKSO”. Our application has been approved subject to, among other things, the closing of the offering described herein and the satisfaction of related administrative conditions."
http://ir.eksobionics.com/all-sec-filings#document-11517-0001144204-16-117206
I'm long EKSO
Canadian University Studying Use of Exoskeletons Immediately Following SCIs
"Participants in the study will receive 60-minute therapy sessions with an Ekso Bionics exoskeleton two to three times a week, for a total of 25 training hours over an eight- to ten-week period. Safety and feasibility outcomes will be monitored and tracked by the research team throughout the sessions."
Full Story:
http://www.oandp.com/articles/NEWS_2016-08-08_02.asp
--
I'm long EKSO
Why make negative assumptions?
While dilution at a unfavorable price is in fact, a possibility -- it's also possible that the offering will be at a higher price than the stock's current market value
Previous dilution was announced just like you said. The last time it happened it was a direct offering.
The fact that this announcement is a public offering at an unannounced price doesn't mean the price will be favorable, but it's at least still an option to what will happen. I see this as a positive change.
I'm going to take my guess that pilot sales, FDA approval, a new ceo, and pending NASDAQ up-listing point towards a much more favorably negotiated price than prior offerings.
Worst case, even if the price is slightly unfavorable; it is equally true that it presents a buying opportunity.
I don't expect this to be the case, but I do have some buying power saved.
I'm long EKSO
It's possible we may see a bidding war between institutions to get in while the getting is still good.
I'm not certain, but I get feeling in my stomach we're about to see an unprecedented rise.
I'm long EKSO
This is absolutely huge!!!! Thoughts on where the price is going tomorrow?
I'm long EKSO
http://www.nasdaq.com/press-release/ekso-bionics-holdings-announces-proposed-public-offering-of-common-stock-20160808-00935
THIS IS ABSOLUTELY PERFECT NEWS!!!!!!!!!!!!!!!!
Public offering vs private sale is golden.
I'm long EKSO
"Our application has been approved subject to, among other things, the closing of the offering described herein and the satisfaction of related administrative conditions."
REPEAT, EKSO HAS BEEN APPROVED FOR NASDAQ +
Underwritten Public offering of stock
PRESS RELEASE ON PUBLIC OFFERING OF STOCK:
http://ir.eksobionics.com/press-releases/detail/583/ekso-bionics-holdings-announces-proposed-public-offering-of
SEC FILING, REGARDING NASDAQ APPROVAL:
"Our common stock is currently quoted on the OTC Markets under the symbol “EKSO.” The last reported sale price of our common stock on the OTC Markets (OTCQB) on August 5, 2016 was $6.24 per share. We have applied for listing of our common stock on The NASDAQ Capital Market under the symbol “EKSO”. Our application has been approved subject to, among other things, the closing of the offering described herein and the satisfaction of related administrative conditions."
http://ir.eksobionics.com/all-sec-filings#document-11517-0001144204-16-117206
THIS IS THE NEWS WE HAVE BEEN WAITING FOR!!!!!!!!!!
I'm long EKSO
I hadn't listened to the Q2 webcast, but wow - it's GREAT!!!!
8 medical units shipped, and 14 industrial
The industrial numbers are beyond what I was expecting.
So the additional FDA clearance was mostly to do with having arm strength in at least one arm for hemiplegia patients.
*Document in hand* is a big deal. Exoskeletons are not just spinal cord injury rehab devices or mobility devices. They are rehabilitation devices for all sorts of neurological/musculoskeletal disorders - and this FDA approval makes this point more clear to the market.
The company is also changing and expanding their sales team
They have 20 preorders for their smart assist in Europe
Max (CFO) said that he expects Q4 to be much like Q2 - so another big boost is expected it would appear.
The reason EKSO views physical therapists as 'gate keepers' is because when the patient goes home for outpatient therapy - it may well be the same therapy center that used an EKSO GT for their inpatient care to sell them their home use device (hopefully an EKSO too!).
As to NASDAQ, they filed at the end of June. They say they have been in contact with NASDAQ ever since. They won't give a timeline, but they did say they have been 'very happy with our dialogue'.
I think things are going according to plan.
http://eksobionics.equisolvewebcast.com/q2-2016
Im' long EKSO
Various macroscopic changes are tilted in the favor of EKSO too with large numbers of older, skilled works nearing retirement.
Additionally, the military is shifting towards having fewer troops -however they will be better trained and more well geared. The U.S. Army has been testing exoskeletons, just because they will be for SOCOM first doesn't mean they won't eventually get wider usage.
The trend towards advanced robotics is huge, an expanding healthcare market - and a larger demand for US made goods.
The timing is right to advance humans physical capabilities in a radically new, meaningful way.
I'm long EKSO
Patience in waiting for the price to go up is difficult, but look how far we've come.
1) Market expansion via Stroke Approval (EKSO GT approved as a therapy exoskeleton for hemiplegia from stroke)
2) continued DARPA/TALOS contracts still underway
3) 2 new products, both with pilot sales (Ekso Vest/Ekso Aerial) - I also view these as much more approachable compared to the full Ekso Works suit.
4) Additional FDA stroke labeling (I was wrong about Parkinson's/MS labeling - or at least short term)
5) Potential NASDAQ uplisting
All these things have happened with out changing the price too dramatically. I'm sticking by my guns that the TALOS release will be the catalyst we have all been waiting for. That being said, it's still 2 years away.
On a more positive note, that doesn't mean that the price won't react beforehand. As TALOS becomes more imminent, it will likely receive much more press and hype - prerelease.
Further into the future, I'm hoping that a female pilot will be the first user to demonstrate the TALOS suit; sending a message to other countries in the world that discriminate against women still.
I will be sad if the price goes down in the interim between now and 2018, but my long term goal is to load up as many shares as possible between now and then.
I'm long EKSO
Meanwhile, I've updated the intro page slightly!
I'm long EKSO
I'm feeling that we will get an up-listing update soon.
Just a gut feeling with no evidence.
I'm hoping to see $10/share before year end before considering to stay away.
I'm long EKSO
Nice find! I hope it's true.
Long ekso
Extremely relevant to EKSO:
http://www.wwl.com/Disabled-veterans-to-get-more-compensation-next-ye/22824793
I'm long EKSO
EKSO BIONICS HLDGS COM USD0.001(POST REV SPLIT (NASDAQ:EKSO)‘s stock had its “buy” rating reiterated by stock analysts at Rodman & Renshaw in a report released on Sunday.
EKSO BIONICS HLDGS COM USD0.00 (NASDAQ:EKSO) opened at 6.19 on Friday. The stock’s 50 day moving average price is $5.53 and its 200 day moving average price is $5.99. The stock’s market capitalization is $100.17 million. EKSO BIONICS HLDGS COM USD0.00 has a 1-year low of $4.01 and a 1-year high of $11.06.
EKSO BIONICS HLDGS COM USD0.001(POST REV SPLIT (NASDAQ:EKSO) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.33. On average, equities research analysts predict that EKSO BIONICS HLDGS COM USD0.00 will post ($1.35) earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered EKSO BIONICS HLDGS COM USD0.001(POST REV SPLIT from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th.
http://baseballnewssource.com/markets/ekso-bionics-hldgs-com-usd0-001post-rev-split-ekso-stock-rating-reaffirmed-by-rodman-renshaw/53572/
-----
I think the only way we are seeing gains is the HealthSouth deal - otherwise the EPS missing the mark would have pulled us down. (The EPS numbers are negative, which the article fails to mention)
Just my take
I'm long EKSO
Following EKSO for..years; I've never been more excited.
It currently feels like the best possible time in EKSO's long history (at least since I've been watching since late 2014). I feel as if they have gone from being the picked on nerds, to the the commanding leader in the field.
Contrasting this is the fact the stock price is much lower than where it was at before the short attack. I can't believe it's still under $7/share given all the good news.
On a different note, I'm happy with the message board too, it's hard to find intelligent conversations among the spam.
I'm long EKSO.
Institutional ownership increases again: Green Square Capital LLC
from .4% to .5%
http://www.nasdaq.com/symbol/ekso/institutional-holdings/new
Green square manages 1.5 billion in assets
"Today we serve the needs of approximately 100 families throughout the U.S., with more than $1.5 billion under management."
http://www.greensquarecap.com/companyhistory
I'm long EKSO
It's not a stretch to imagine 15m spent for ~100 ekso GT's
Healthsouth serves 120 inpatient rehab hospitals
"Operating in 33 states across the country and in Puerto Rico, HealthSouth serves patients through its network of inpatient rehabilitation hospitals (120), outpatient rehabilitation satellite clinics (29), and home health and hospice agencies (165)."
- from wiki
I'm long EKSO
I think we can expect specifics soon. The GT is already in production - unlike the industrial/TALOS divisions.
I'm thinking rental is more likely than purchasing.
The real key with this deal is that Healthsouth will likely be able to train it's own staff.
Previously, EKSO had to spend time with the physical therapists in order to train them at each individual rehab center/hospital.
This should put a real boost on things, and short term
I'm long EKSO
"HealthSouth Corporation, based in Birmingham, Alabama, is the United States' largest owner and operator of inpatient rehabilitative hospitals."
from wiki
Who the hell cares about this quarters earnings after locking down a contract with the largest inpatient rehab hospital group in the entire US?
I'm long EKSO
Vending to a $3.8 billion market cap company will provide Ekso a meaningful boost in revenue, correct?
I'm long EKSO
I really think we might see $7 next week
The timing is right to break back out.
A press release with specifics of the HealthSouth deal would be huge.
They might easily rent/purchase hundreds of EKSO GT's!!!!
This is the news we have been waiting for.
Don't be disheartened we didn't see more of a jump today. The whole market was slightly down, and the institutions often don't get around to press releases day of.
I'm long EKSO
That's crazy. Additional label expansion plus supplying Healthsouth is a HUGE deal.
I expect the stock to take some time to react, but for a big bump upon press releases and contract completions.
I'm long EKSO
Ekso now has "an agreement in place as a vendor to Healthsouth, one of the nation’s largest private providers of post-acute healthcare services."
-from the earnings report press release
Very big news, Healthsouth has a market cap over 3 billion (see HLS stock)
"additional clearance granted July 19, 2016 expanding label and further widening reach among stroke patients in the rehabilitation setting."
http://ir.eksobionics.com/press-releases/detail/582
Good news!!
Ekso Bionics is continuing to hire. A new job was even listed today.
Sr Embedded Systems Engineer & Office Administrator
https://eksobionics-openhire.silkroad.com/epostings/index.cfm?fuseaction=app.jobsearch
I plan to purchase more EKSO stock shortly
My fingers are crossed for the earnings report tomorrow.
Hopefully some sort of update on the industrial division sales to BMW